Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Simcere Pharmaceutical Group: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

13 Dec 2013 Reuters Investment Profile 12 $20.00

Simcere Pharmaceuticals ADR

25 Dec 2013 S&P Capital IQ Quantitative Report 6 $69.00

ValuEngine Detailed Valuation Report for SCR

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

24 Dec 2013 ValuEngine, Inc. 11 $25.00

TheStreet.com Ratings Stock Report For: SIMCERE PHARMACTCL GRP -ADR (SCR)

22 Dec 2013 TheStreet.com Ratings 5 $10.00

SCR - Simcere Pharmaceutical Group - Rated a Hold - Company Analysis and ASR Ranking Report

www.AlphaStreetResearch.com - Full Coverage of 3,000 U.S. equities. Reports include Financials, Ratios, Competitor Comparison...

21 Dec 2013 Alpha Street Research 9 $24.00

Validea Guru Analysis Report for SCR. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others.

Validea's Guru Stock Report uses an interpretation of the published stock-picking strategies developed by 10 investing legend...

20 Dec 2013 Validea 0 $12.00

SIMCERE PHARMAC (SCR) Zacks Company Snapshot

16 Dec 2013 Zacks Investment Research Inc. 1 $12.00

TheStreet.com Ratings Stock Report For: SIMCERE PHARMACTCL GRP -ADR (SCR)

15 Dec 2013 TheStreet.com Ratings 5 $10.00

Simcere Pharmaceutical Group (SCR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Simcere Pharmaceutical Group (SCR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Summary Simcere Pharmaceutica...

13 Dec 2013 GlobalData 46 $250.00

TheStreet.com Ratings Stock Report For: SIMCERE PHARMACTCL GRP -ADR (SCR)

08 Dec 2013 TheStreet.com Ratings 5 $10.00